Cytori Therapeutics Acquires Assets Of Azaya Therapeutics

Image result for Cytori Therapeutics

Cytori Therapeutics ($CYTX) announced the acquisition of certain assets from Azaya Therapeutics, which is a privately held firm. Under the terms of the deal, Cytori will issue $2 million in Cytori common stock up front. It will also assume nearly $2 million of Azaya’s trade payables.
The overall value of the deal is projected to be nearly $170 million, which includes milestone payments and potential royalties. The deal is likely to close by the end of February.
Cytori says the deal will provide it with a proprietary liposomal nanoparticle technology which will help augmenting its position in regenerative medicine. These products include ATI-0918, a nanoparticle liposomal formulation of doxorubicin hydrochloride for treating breast cancer, Kaposi’s sarcoma, multiple myeloma, and ovarian cancer.
The other important product acquired under the deal is ATI-1123, another nanoparticle-stabilized liposomal formulation of docetaxel intended to treat solid tumor cancers of patients who have failed other therapies. Docetaxel’s global market is estimated to be worth $1.3 billion.
The company stock has gained nearly 2% this year so far. However, it is still trading way below its 52 weeks high of $5.44. Cytori also recently released topline review of early three-year follow-up data from the SCLERADEC I trial. The review showed sustained benefit in treated patients over baseline in major study endpoints, which offers another attractive opportunity for the company.

Subscribe to KKD Healthcare Analytics for an entire Biotech digest. 

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.